Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea

American Journal of Hematology

Volumn 51, Issue 2, 1996, Pages 137-140

  Furgerson, James L ^a   Vukelja, Svetislava J ^a   Baker, W Jeffrey ^a   O'Rourke, Timothy J ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Chromosomal aberrations; Essential thrombocythemia; Hydroxyurea; Therapy associated leukemia; Thrombocytosis

Indexed keywords

CYTARABINE; HYDROXYUREA; MITOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CHROMOSOME ABERRATION; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTHEMIA;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0030064767     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199602)51:2<137::AID-AJH7>3.0.CO;2-Z     Document Type: Article

References (30)

1. Epstein E, Goedel A: Hamorrhagishe Thrombocythamic bei vasularer Schrumpfmilz. Virchows Arch [Pathol Anat] 292:233-248, 1934.
2. Iand HJ, Laszlo J, Peterson P, Murphy S, Briere J, Weinfeld A, Rosenthal DS, Landaw SA, Ellis JT, Silverstein MN: Essential thrombocythemia. Clinical and laboratory characteristics at presentation. Trans Asoc Am Physicians 96:165, 1983.
3. Murphy S, Iland H, Rosenthal D: Essential thrombocythemia: An interim report from the polycythemia vera study group. Semin Hematol 23:177, 1986.
4. Landaw SA: Acute leukemia in polycythemia vera. Semin Hematol 23:156-165, 1986.
5. Rosner F Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer 37:133-136, 1976.
6. Bellucci S, Janvier M, Tobelem G, Flandrin G, Chazpak Y, Berger R, Boiron M: Essential thrombocythemias. Clinical, evolutionary and biological data. Cancer 58:2440, 1986
7. Chabner BA, Collins JM (eds): "Cancer Chemotherapy: Principles and Practice." Philadelphia: J B. Lippincott, 1990, pp 225-233.
8. Kantarjian HM, Keating MJ: Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14:435-443, 1987.
9. Levine EG, Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47-84, 1992.
10. Coltman CA, Dixon DO: Second malignancies complicating Hodgkin's disease A Southwest Oncology Group 10 year followup. Cancer Treat Rep 66:1023-1033, 1982
11. Green MH, Young RC, Merrill JM, DeVita VT: Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma Cancer Res 43:1891-1898, 1983.
12. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR: Long term management of polycythemia vera with hydroxyurea: A progress report. Semin Hematol 23:167-171, 1986.
13. Holcombe RF, Treseler PA, Rosenethal DS: Chronic myelomonocytic leukemia transformation in polycythemia vera. Leukemia 5:606-610, 1991.
14. Landlaw SA: Acute leukemia in polycythemia vera. In Wasserman LR, Berk PD, Berlin NI (eds): "Polycythemia Vera and the Myeloproliferative Disorders" Philadelphia: W.B. Saunders, 1995, pp 154-165.
15. Sedlacek SM, Curtis JL, Weintraub J, Levin J: Essential thrombocythemia and leukemic transformation. Medicine (Baltimore) 65:353-364, 1986.
16. Geller SA, Shapiro E: Acute leukemia is a natural sequel to primary thrombocythemia Am J Clin Pathol 77:353-356, 1982.
17. Mitus AJ, Schafer AI: Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 4:157-178, 1990.
18. Pedersen-Bjergaard J, Phillip P, Larsen SO, Jensen G, Byrsting K: Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute non-lymphocytic leukemia. Blood 76:1083-1091, 1990.
19. Rowley JD: Chromosome changes in leukemia cells as indicators of mutagenic exposure. In Rowley JD, Ultmann JE (eds): "Chromosomes and Cancer. From Molecules to Man." New York: Academic Press, 1983, pp 139-159.
20. Yunis JJ: The chromosomal basis of human neoplasia. Science 221:227-236, 1983.
21. Lofvenberg E, Nordenson I, Wahlin A: Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet 49:57-67, 1990.
22. Van den Anker-Lugtenburg PJ, Sizoo W: Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea. Am J Hematol 33:152, 1990.
23. Reiffers J, Dachary D, David B, Bernard P, Marit G, Boisseau M. Braustet A: Megakaryoblastic transformation of primary thrombocytherma. Acta Haematol (Basel) 73:228-231, 1985.
24. Weinfeld A, Swolin B, Weslin J: Acute leukemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of leukaemogenicity with therapeutic implications. Eur J Haematol 52:134-139, 1994.
25. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Gali M. Rodeghiero F, Barbui T: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.
26. Hehlmann R, Jahn M, Baumann B. Essential thrombocythemia: Clinical characteristics and course of 61 cases. Cancer 61:2487, 1988.
27. Hoagland HC, Silverstein MN: Primary thrombocythemia in the young patient. Mayo Clin Proc 53.578, 1978.
28. Silverstein M, Pettit R, Solberg L, Fleming JS, Knight R, Schacter L: Anegralide: A new drug for treating thrmobocytosis. N Engl J Med 318:1292-1294, 1988.
29. Vichinsnky EP, Lubin BH: A cautionary note regarding hydroxyurea in sickle cell disease Blood 83:1124-1128, 1994.
30. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73-80, 1993.